New Multiplex Panels from Aushon BioSystems Help Measure Urinary Biomarkers of Kidney Damage during Drug Development
Aushon BioSystems, Inc., a provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.
The Human Nephrotoxicity Panels are validated for analysis of urine samples. The panels were developed using the Aushon SearchLight® protein array technology – a multiplex, sandwich ELISA system based on chemiluminescent or infrared detection of analytes. It features a 3.5 hour protocol that is very similar to protocols for traditional plate-based ELISA kits.
The new multiplex panels include the following biomarkers:
• KIM-1, Clusterin, TIMP-1, VEGF, Trefoil Factor-3 (TFF-3), Osteopontin, EGF, NGAL
Researchers can analyze samples from clinical trials using Aushon’s CLIA-certified sample testing service or conduct the analysis themselves using Aushon’s chemiluminescent biomarker kits and imaging system.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
